JP2016523862A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523862A5 JP2016523862A5 JP2016521580A JP2016521580A JP2016523862A5 JP 2016523862 A5 JP2016523862 A5 JP 2016523862A5 JP 2016521580 A JP2016521580 A JP 2016521580A JP 2016521580 A JP2016521580 A JP 2016521580A JP 2016523862 A5 JP2016523862 A5 JP 2016523862A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- pridopidine
- patient
- uhdrs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837928P | 2013-06-21 | 2013-06-21 | |
| US61/837,928 | 2013-06-21 | ||
| US201361877832P | 2013-09-13 | 2013-09-13 | |
| US61/877,832 | 2013-09-13 | ||
| PCT/US2014/043204 WO2014205229A1 (en) | 2013-06-21 | 2014-06-19 | Use of high dose pridopidine for treating huntington's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016523862A JP2016523862A (ja) | 2016-08-12 |
| JP2016523862A5 true JP2016523862A5 (enExample) | 2017-08-03 |
Family
ID=52105289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521580A Withdrawn JP2016523862A (ja) | 2013-06-21 | 2014-06-19 | ハンチントン病を治療するための高用量プリドピジンの使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10322119B2 (enExample) |
| EP (1) | EP3010506B1 (enExample) |
| JP (1) | JP2016523862A (enExample) |
| KR (1) | KR102316933B1 (enExample) |
| CN (1) | CN105592848A (enExample) |
| AU (1) | AU2014281414A1 (enExample) |
| BR (1) | BR112015029918A2 (enExample) |
| CA (1) | CA2913781C (enExample) |
| CL (1) | CL2015003690A1 (enExample) |
| DK (1) | DK3010506T3 (enExample) |
| EA (1) | EA201690069A1 (enExample) |
| ES (1) | ES2879631T3 (enExample) |
| HK (1) | HK1221646A1 (enExample) |
| HU (1) | HUE054783T2 (enExample) |
| IL (1) | IL242804B (enExample) |
| MX (1) | MX384234B (enExample) |
| PE (2) | PE20170302A1 (enExample) |
| PH (1) | PH12015502691A1 (enExample) |
| PL (1) | PL3010506T3 (enExample) |
| SG (1) | SG11201509729YA (enExample) |
| TW (1) | TW201529069A (enExample) |
| UA (1) | UA122999C2 (enExample) |
| UY (1) | UY35624A (enExample) |
| WO (1) | WO2014205229A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2937243C (en) * | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| EP3324967A4 (en) * | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| EP3419622B1 (en) | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| CN110012661A (zh) * | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| AU2017326436A1 (en) * | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| ES2972205T3 (es) | 2017-01-20 | 2024-06-11 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento del síndrome x frágil |
| US20260091028A1 (en) * | 2017-08-14 | 2026-04-02 | Prilenia Neurotherapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with pridopidine |
| HUE061505T2 (hu) * | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| JP2020532517A (ja) * | 2017-08-30 | 2020-11-12 | プリレニア ニューロセラピューティクス リミテッド | 高濃度プリドピジン製剤 |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3917380B1 (en) * | 2019-01-31 | 2025-03-19 | F. Hoffmann-La Roche AG | Assessing progression of huntington's disease |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| SMT202600016T1 (it) * | 2019-06-12 | 2026-03-09 | Prilenia Neurotherapeutics Ltd | Composizione contenente pridopidina e un suo analogo per il trattamento della malattia di huntington e dei suoi sintomi |
| CN114727761A (zh) * | 2019-09-17 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 患有运动障碍的患者的个性化保健的改善 |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| WO2022094565A1 (en) * | 2020-10-28 | 2022-05-05 | Buck Institute For Research On Aging | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders |
| CA3214354A1 (en) * | 2021-04-14 | 2022-10-20 | Michael Hayden | Treatment of prodromal huntington disease |
| WO2025181805A1 (en) * | 2024-02-27 | 2025-09-04 | Prilenia Neurotherapeutics Ltd. | Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| EP1713486A4 (en) | 2003-12-02 | 2009-04-29 | Sheldon Leslie James | COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| EP1815857A1 (en) * | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| WO2010008486A2 (en) | 2008-06-24 | 2010-01-21 | Parkinsons Institute | Pluripotent cell lines and methods of use thereof |
| US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX343620B (es) | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| US20150209346A1 (en) | 2012-09-27 | 2015-07-30 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| MX2015003812A (es) | 2012-09-27 | 2015-07-17 | Teva Pharma | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. |
| CA2937243C (en) | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
-
2014
- 2014-06-19 CA CA2913781A patent/CA2913781C/en active Active
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/en active Active
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active Active
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-19 MX MX2015017307A patent/MX384234B/es unknown
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 HK HK16109788.9A patent/HK1221646A1/zh unknown
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/en not_active Ceased
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
-
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| NZ708526A (en) | Novel rock inhibitors | |
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2013520405A5 (enExample) | ||
| EA201390827A1 (ru) | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом | |
| JP2017528507A5 (enExample) | ||
| EA201370230A1 (ru) | Новые ингибиторы rock | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| RU2017114352A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| JP2017506624A5 (enExample) | ||
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| JP2015505564A5 (enExample) | ||
| JP2011225596A5 (enExample) | ||
| EA201590726A1 (ru) | Лахинимод для уменьшения таламического поражения при рассеянном склерозе | |
| JP2017526695A5 (enExample) | ||
| JP2008509224A5 (enExample) | ||
| JP2016510343A5 (enExample) | ||
| JP2021503483A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. |